Literature DB >> 25550231

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

N Singewald1, C Schmuckermair2, N Whittle2, A Holmes3, K J Ressler4.   

Abstract

Pathological fear and anxiety are highly debilitating and, despite considerable advances in psychotherapy and pharmacotherapy they remain insufficiently treated in many patients with PTSD, phobias, panic and other anxiety disorders. Increasing preclinical and clinical evidence indicates that pharmacological treatments including cognitive enhancers, when given as adjuncts to psychotherapeutic approaches [cognitive behavioral therapy including extinction-based exposure therapy] enhance treatment efficacy, while using anxiolytics such as benzodiazepines as adjuncts can undermine long-term treatment success. The purpose of this review is to outline the literature showing how pharmacological interventions targeting neurotransmitter systems including serotonin, dopamine, noradrenaline, histamine, glutamate, GABA, cannabinoids, neuropeptides (oxytocin, neuropeptides Y and S, opioids) and other targets (neurotrophins BDNF and FGF2, glucocorticoids, L-type-calcium channels, epigenetic modifications) as well as their downstream signaling pathways, can augment fear extinction and strengthen extinction memory persistently in preclinical models. Particularly promising approaches are discussed in regard to their effects on specific aspects of fear extinction namely, acquisition, consolidation and retrieval, including long-term protection from return of fear (relapse) phenomena like spontaneous recovery, reinstatement and renewal of fear. We also highlight the promising translational value of the preclinial research and the clinical potential of targeting certain neurochemical systems with, for example d-cycloserine, yohimbine, cortisol, and L-DOPA. The current body of research reveals important new insights into the neurobiology and neurochemistry of fear extinction and holds significant promise for pharmacologically-augmented psychotherapy as an improved approach to treat trauma and anxiety-related disorders in a more efficient and persistent way promoting enhanced symptom remission and recovery.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Augmented relearning; Cognitive enhancer; Drug development; Exposure therapy; Fear extinction; Reconsolidation

Mesh:

Substances:

Year:  2014        PMID: 25550231      PMCID: PMC4380664          DOI: 10.1016/j.pharmthera.2014.12.004

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  562 in total

Review 1.  Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome.

Authors:  R D Kornberg; Y Lorch
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

2.  GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning.

Authors:  G E Stutzmann; J E LeDoux
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

3.  Regional distribution of Y-receptor subtype mRNAs in rat brain.

Authors:  R M Parker; H Herzog
Journal:  Eur J Neurosci       Date:  1999-04       Impact factor: 3.386

4.  GABAB-receptor splice variants GB1a and GB1b in rat brain: developmental regulation, cellular distribution and extrasynaptic localization.

Authors:  J M Fritschy; V Meskenaite; O Weinmann; M Honer; D Benke; H Mohler
Journal:  Eur J Neurosci       Date:  1999-03       Impact factor: 3.386

5.  A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex.

Authors:  V L Arvanov; X Liang; P Magro; R Roberts; R Y Wang
Journal:  Eur J Neurosci       Date:  1999-08       Impact factor: 3.386

Review 6.  The neuroanatomical and neurochemical basis of conditioned fear.

Authors:  M Fendt; M S Fanselow
Journal:  Neurosci Biobehav Rev       Date:  1999-05       Impact factor: 8.989

7.  Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release.

Authors:  G K Aghajanian; G J Marek
Journal:  Brain Res       Date:  1999-04-17       Impact factor: 3.252

8.  Serotonergic modulation of neurotransmission in the rat basolateral amygdala.

Authors:  D G Rainnie
Journal:  J Neurophysiol       Date:  1999-07       Impact factor: 2.714

9.  The role of mesoprefrontal dopamine neurons in the acquisition and expression of conditioned fear in the rat.

Authors:  B A Morrow; J D Elsworth; A M Rasmusson; R H Roth
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

10.  Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat.

Authors:  V Cornea-Hébert; M Riad; C Wu; S K Singh; L Descarries
Journal:  J Comp Neurol       Date:  1999-06-28       Impact factor: 3.215

View more
  108 in total

1.  Dnmt3a2: a hub for enhancing cognitive functions.

Authors:  A M M Oliveira; T J Hemstedt; H E Freitag; H Bading
Journal:  Mol Psychiatry       Date:  2015-11-24       Impact factor: 15.992

2.  The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats.

Authors:  Mano Aliczki; Istvan Barna; Ibolya Till; Maria Baranyi; Beata Sperlagh; Steven R Goldberg; Jozsef Haller
Journal:  Psychopharmacology (Berl)       Date:  2016-01-26       Impact factor: 4.530

Review 3.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

4.  Extinction of Contextual Cocaine Memories Requires Cav1.2 within D1R-Expressing Cells and Recruits Hippocampal Cav1.2-Dependent Signaling Mechanisms.

Authors:  Caitlin E Burgdorf; Kathryn C Schierberl; Anni S Lee; Delaney K Fischer; Tracey A Van Kempen; Vladimir Mudragel; Richard L Huganir; Teresa A Milner; Michael J Glass; Anjali M Rajadhyaksha
Journal:  J Neurosci       Date:  2017-10-31       Impact factor: 6.167

Review 5.  L-type Ca2+ channels in mood, cognition and addiction: integrating human and rodent studies with a focus on behavioural endophenotypes.

Authors:  Z D Kabir; A S Lee; A M Rajadhyaksha
Journal:  J Physiol       Date:  2016-04-24       Impact factor: 5.182

Review 6.  Emotional Modulation of Learning and Memory: Pharmacological Implications.

Authors:  Ryan T LaLumiere; James L McGaugh; Christa K McIntyre
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 7.  Transcriptional Regulation Involved in Fear Memory Reconsolidation.

Authors:  Xu Wang; Min Li; Haitao Zhu; Yongju Yu; Yuanyuan Xu; Wenmo Zhang; Chen Bian
Journal:  J Mol Neurosci       Date:  2018-05-23       Impact factor: 3.444

Review 8.  Diminishing fear: Optogenetic approach toward understanding neural circuits of fear control.

Authors:  Natalia V Luchkina; Vadim Y Bolshakov
Journal:  Pharmacol Biochem Behav       Date:  2017-05-11       Impact factor: 3.533

9.  Effects of a histone deacetylase 3 inhibitor on extinction and reinstatement of cocaine self-administration in rats.

Authors:  Leah N Hitchcock; Jonathan D Raybuck; Marcelo A Wood; K Matthew Lattal
Journal:  Psychopharmacology (Berl)       Date:  2018-11-28       Impact factor: 4.530

10.  Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial.

Authors:  Kate R Kuhlman; Michael Treanor; Gabriella Imbriano; Michelle G Craske
Journal:  Psychoneuroendocrinology       Date:  2020-03-20       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.